Research brief • May 14, 2026

Retatrutide “GLP-3” and MOTS-c Evidence Map

Today’s video topic paired retatrutide, often nicknamed “GLP-3” online, with MOTS-c. Both are discussed in peptide communities, but the evidence base behind each topic is very different. Retatrutide sits in a clinical-trial pipeline. MOTS-c remains more mechanism-first, with a smaller human-trial footprint.

Educational disclaimer: This article is for research literacy only and is not medical advice. It does not provide dosing, protocols, treatment plans, reconstitution instructions, sourcing instructions, or recommendations to buy or use any compound. Affiliate disclosure: I may earn a commission from links on this site, at no extra cost to you.

Free research kit

Save the COA and claim-checking prompts.

Get education-first checklists before you evaluate supplier pages or social claims.

Get the free research kit

Why these two topics were grouped together

The midnight PDR video plan used five short angles around a single theme: online peptide trends can make very different research categories sound equally proven. Retatrutide trends because it is an investigational multi-receptor incretin candidate with published Phase 2 studies. MOTS-c trends because it connects to mitochondrial biology, exercise signaling, metabolic pathways, and aging-related research narratives.

The useful question is not “which one is exciting?” It is: what kind of evidence exists, what endpoints were measured, and where do social-media claims move beyond the source material?

The plain-English snapshot

Retatrutide, also called LY3437943, is being studied as a GIP, GLP-1, and glucagon receptor agonist.
“GLP-3” is a popular online nickname, not the formal scientific name and not an approval category.
Published retatrutide papers include Phase 2 research in obesity and type 2 diabetes, plus Phase 2a metabolic liver-disease research.
MOTS-c is a mitochondrial-derived peptide studied around metabolic homeostasis, stress response, exercise biology, and aging-related mechanisms.
Retatrutide currently has a more mature human clinical-development record than MOTS-c.

Retatrutide: the clinical-development side

Retatrutide is designed to interact with three receptor systems: GIP, GLP-1, and glucagon. That triple-receptor design explains why the internet sometimes calls it “GLP-3.” The nickname is catchy, but it can also hide the important details. Retatrutide is not simply a consumer peptide trend; it is an investigational drug candidate being evaluated through structured clinical research.

Fresh source checks today found PubMed-indexed Phase 2 publications for obesity and type 2 diabetes, a Phase 2a paper focused on metabolic dysfunction-associated steatotic liver disease, and multiple ClinicalTrials.gov listings involving obesity, cardiovascular disease, body composition, kidney function, and related endpoints. That does not mean readers should infer approval, availability, or personal suitability. It means the evidence conversation should stay anchored to trial design, measured endpoints, adverse-event reporting, and regulator-facing data.

MOTS-c: the mechanism-first side

MOTS-c is discussed in scientific literature as a mitochondrial-derived peptide. Researchers have explored it in relation to cellular energy signaling, metabolic homeostasis, skeletal muscle biology, stress-response pathways, and exercise-related biology. Those are research-significant topics, but mechanism data should not be confused with proven human outcomes.

Today’s ClinicalTrials.gov check showed a much smaller and less mature trial footprint for MOTS-c than for retatrutide. PubMed searches show a broader base of mechanistic papers, reviews, and model-based work. That makes MOTS-c worth tracking as a research-literacy topic, while keeping the language careful: “studied in relation to” is different from “shown to improve” or “recommended for.”

Evidence map: what each topic can and cannot support

Retatrutide can support

Discussion of published clinical trials, receptor targets, enrolled populations, trial endpoints, tolerability reporting, and future Phase 3 or regulatory checkpoints.

Retatrutide cannot support

Claims that a reader should use it, that results are guaranteed, that it is broadly approved for every online claim, or that dosing/protocol advice belongs in general content.

MOTS-c can support

Discussion of mitochondrial-derived peptide biology, metabolic signaling hypotheses, exercise-related research, model systems, and early clinical questions.

MOTS-c cannot support

Broad anti-aging, fat-loss, disease-treatment, or performance claims that outrun controlled human evidence and regulatory review.

How readers should filter social claims

A simple research filter helps: identify the compound, the study type, the population, the endpoint, and the publication or registry source. A Phase 2 randomized trial, a mechanistic cell paper, an animal model, a conference headline, a company release, and an affiliate sales page are not the same kind of evidence.

For retatrutide, the most important next checkpoints are larger trial readouts, safety and tolerability patterns, body-composition data, cardiometabolic endpoints, liver-disease endpoints, and regulator decisions. For MOTS-c, the key checkpoint is whether controlled human studies can connect the mechanism story to defined, reproducible endpoints.

Research-only supplier note

If readers compare research suppliers, the responsible questions are documentation, posted testing, COA transparency, labeling clarity, and legal/regulatory fit. This is not a recommendation to purchase, use, dose, inject, or combine any compound.

View research supplier

Affiliate disclosure: I may earn a commission. Educational content only — not medical advice.

Sources checked

Keep learning

Peptide Daily Report tracks peptide research with a simple standard: explain what the source says, what it does not say, and how to avoid confusing marketing language with evidence.

Get the free research kit

Compare research supplier transparencyReview documentation, posted testing, and claim boundaries →View posted COA sourcesUse the checklist before trusting purity or content claims →See trusted sourcesAffiliate disclosure applies; independently verify every source →

New education-first briefs weekly

Get the free research kit.

COA prompts, supplier due-diligence notes, and article drops. No dosing, protocols, or medical advice.